|
|
|
|
|
| (11) | Liudijimo numeris | C 3710439 |
| (68) | Patento numeris | 3710439 |
| (21) | Paraiškos papildomos apsaugos liudijimui gauti numeris | PA 2024 517 |
| (22) | Paraiškos papildomos apsaugos liudijimui gauti padavimo data | 2024-06-11 |
| (41) | Paraiškos papildomos apsaugos liudijimui gauti paskelbimo data | 2024-07-10 |
| Liudijimo paskelbimo data | 2025-11-25 | |
| (24) | Liudijimo įsigaliojimo data | 2038-11-15 |
| (71) |
Mirati Therapeutics, Inc. ,
9393 Towne Centre Drive
Suite 200, San Diego, CA 92121,
US
Array Biopharma Inc. , 3200 Walnut Street, Boulder, CO 80301, US |
| (73) |
Mirati Therapeutics, Inc. ,
9393 Towne Centre Drive
Suite 200, San Diego, CA 92121,
US
Array Biopharma Inc. , 3200 Walnut Street, Boulder, CO 80301, US |
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (93) | EU/1/23/1744, 2024-01-05 |
| (94) | 2039-01-09 |
| (95) | Adagrasibas arba farmaciniu požiūriu priimtina jo druska |
| PAL išduotas |